Boston Scientific Corporation $BSX Stake Boosted by Eventide Asset Management LLC

Key Points

• Eventide Asset Management LLC increased its stake in Boston Scientific Corporation by 17.9%, owning 32,123 shares worth approximately $3,231,000 as of the end of the first quarter.
• Several other institutional investors also made significant moves in Boston Scientific, with a collective 89.07% of the company's stock now held by institutional investors.
• Research analysts have generally rated Boston Scientific positively, with a consensus Buy rating and a price target averaging $117.50 following recent price target increases from various firms.

Eventide Asset Management LLC lifted its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 17.9% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 32,123 shares of the medical equipment provider's stock after buying an additional 4,886 shares during the period. Eventide Asset Management LLC's holdings in Boston Scientific were worth $3,231,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Cinctive Capital Management LP bought a new position in shares of Boston Scientific during the 1st quarter worth about $10,447,000. Clark Capital Management Group Inc. grew its position in shares of Boston Scientific by 144.3% during the 1st quarter. Clark Capital Management Group Inc. now owns 11,333 shares of the medical equipment provider's stock valued at $1,143,000 after purchasing an additional 6,694 shares in the last quarter. Concentric Capital Strategies LP purchased a new position in Boston Scientific in the first quarter worth $4,080,000. Alliancebernstein L.P. grew its position in Boston Scientific by 64.3% in the first quarter. Alliancebernstein L.P. now owns 3,036,935 shares of the medical equipment provider's stock worth $306,366,000 after acquiring an additional 1,189,016 shares in the last quarter. Finally, AQR Capital Management LLC lifted its stake in Boston Scientific by 26.7% in the first quarter. AQR Capital Management LLC now owns 1,155,829 shares of the medical equipment provider's stock worth $114,427,000 after purchasing an additional 243,893 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Price Performance

BSX traded up $0.92 during midday trading on Monday, hitting $108.14. 7,454,396 shares of the company traded hands, compared to its average volume of 5,736,611. The business has a 50 day simple moving average of $104.77 and a two-hundred day simple moving average of $102.15. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $160.23 billion, a price-to-earnings ratio of 64.37, a PEG ratio of 2.58 and a beta of 0.65. Boston Scientific Corporation has a 52-week low of $80.64 and a 52-week high of $108.94.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. During the same period last year, the business earned $0.62 earnings per share. Boston Scientific's revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the company's stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the transaction, the director directly owned 2,081 shares of the company's stock, valued at $222,646.19. This represents a 58.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 174,214 shares of company stock valued at $18,397,457. 0.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have recently commented on BSX. Barclays upped their price objective on shares of Boston Scientific from $125.00 to $133.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. Morgan Stanley increased their price target on shares of Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a report on Friday, May 16th. Leerink Partnrs upgraded shares of Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Needham & Company LLC reiterated a "buy" rating and set a $115.00 price target on shares of Boston Scientific in a research note on Wednesday, May 28th. Finally, Jefferies Financial Group restated a "hold" rating on shares of Boston Scientific in a research note on Monday, July 21st. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Boston Scientific currently has an average rating of "Buy" and a consensus target price of $117.79.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.